Travere Therapeutics (NASDAQ:TVTX) CEO Eric Dube Sells 51,865 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric Dube sold 51,865 shares of the firm’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $30.10, for a total value of $1,561,136.50. Following the transaction, the chief executive officer directly owned 419,173 shares of the company’s stock, valued at $12,617,107.30. This represents a 11.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Travere Therapeutics Stock Up 0.3%

NASDAQ:TVTX opened at $30.03 on Wednesday. The company has a debt-to-equity ratio of 4.23, a current ratio of 2.75 and a quick ratio of 2.71. The firm’s 50-day moving average price is $34.46 and its 200-day moving average price is $27.22. The company has a market capitalization of $2.69 billion, a PE ratio of -28.33, a P/E/G ratio of 0.98 and a beta of 0.85. Travere Therapeutics, Inc. has a 1-year low of $12.91 and a 1-year high of $42.13.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Thursday, October 30th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.31) by $0.59. Travere Therapeutics had a negative net margin of 20.32% and a negative return on equity of 178.68%. The business had revenue of $164.86 million for the quarter, compared to analyst estimates of $106.09 million. During the same quarter in the previous year, the firm posted ($0.70) earnings per share. Travere Therapeutics’s quarterly revenue was up 162.1% on a year-over-year basis. On average, equities analysts predict that Travere Therapeutics, Inc. will post -1.4 EPS for the current fiscal year.

Analyst Ratings Changes

TVTX has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Travere Therapeutics in a research note on Wednesday, January 21st. Piper Sandler lifted their price target on Travere Therapeutics from $26.00 to $35.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. TD Cowen reissued a “buy” rating on shares of Travere Therapeutics in a research report on Friday, October 31st. Wall Street Zen upgraded shares of Travere Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 13th. Finally, Guggenheim reiterated a “buy” rating and issued a $49.00 target price on shares of Travere Therapeutics in a research note on Wednesday, January 14th. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Travere Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $38.86.

Hedge Funds Weigh In On Travere Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of TVTX. Vanguard Group Inc. boosted its stake in shares of Travere Therapeutics by 10.3% in the 3rd quarter. Vanguard Group Inc. now owns 6,613,368 shares of the company’s stock worth $158,059,000 after buying an additional 619,085 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its position in Travere Therapeutics by 27.4% in the second quarter. Adage Capital Partners GP L.L.C. now owns 2,784,000 shares of the company’s stock worth $41,203,000 after buying an additional 599,102 shares in the last quarter. Emerald Advisers LLC raised its stake in shares of Travere Therapeutics by 2.6% in the third quarter. Emerald Advisers LLC now owns 2,146,767 shares of the company’s stock worth $51,308,000 after buying an additional 55,407 shares during the period. Geode Capital Management LLC lifted its position in shares of Travere Therapeutics by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 2,003,701 shares of the company’s stock valued at $29,658,000 after buying an additional 27,040 shares in the last quarter. Finally, Stephens Investment Management Group LLC purchased a new position in shares of Travere Therapeutics during the 3rd quarter valued at about $38,232,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.